Lexicon Pharmaceuticals, Inc.
LXRX
$1.40
$0.064.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,255.21% | 1,504.83% | 1,250.63% | 2,479.34% | 884.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,255.21% | 1,504.83% | 1,250.63% | 2,479.34% | 884.75% |
| Cost of Revenue | 8.62% | 53.46% | 13.72% | -6.30% | -24.03% |
| Gross Profit | 158.85% | 110.52% | 48.08% | 58.15% | 32.41% |
| SG&A Expenses | -65.06% | -39.39% | -11.17% | 17.20% | 45.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.63% | -17.44% | 5.12% | 25.88% | 37.92% |
| Operating Income | 73.98% | 45.77% | 10.48% | -8.52% | -35.02% |
| Income Before Tax | 68.31% | 40.32% | 8.41% | -13.15% | -37.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.31% | 40.32% | 8.41% | -13.15% | -37.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.31% | 40.32% | 8.41% | -13.15% | -37.08% |
| EBIT | 73.98% | 45.77% | 10.48% | -8.52% | -35.02% |
| EBITDA | 74.21% | 45.92% | 10.50% | -8.56% | -35.11% |
| EPS Basic | 74.80% | 57.15% | 37.70% | 19.54% | 0.62% |
| Normalized Basic EPS | 79.15% | 61.21% | 41.40% | 23.22% | 1.35% |
| EPS Diluted | 74.80% | 57.15% | 37.70% | 19.54% | 0.62% |
| Normalized Diluted EPS | 79.15% | 61.21% | 41.40% | 23.22% | 1.35% |
| Average Basic Shares Outstanding | 24.74% | 38.46% | 48.50% | 44.76% | 40.51% |
| Average Diluted Shares Outstanding | 24.76% | 38.48% | 48.50% | 44.76% | 40.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |